DOCSLIB.ORG

Interferon-Beta Represses Cancer Stem Cell Properties in Triple-Negative Breast Cancer

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Interferon-Beta Represses Cancer Stem Cell Properties in Triple-Negative Breast Cancer Interferon-beta represses cancer stem cell properties in triple-negative breast cancer Mary R. Dohertya,1, HyeonJoo Cheonb, Damian J. Junka,c, Shaveta Vinayakc,d,e, Vinay Varadanc,f, Melinda L. Tellig, James M. Fordg, George R. Starkb,c,1, and Mark W. Jacksona,c,1 aDepartment of Pathology, Case Western Reserve University, School of Medicine, Cleveland, OH 44106; bDepartment of Cancer Biology, Lerner Research Institute, The Cleveland Clinic Foundation, Cleveland, OH 44195; cCase Comprehensive Cancer Center, Case Western Reserve University, School of Medicine, Cleveland, OH 44106; dDepartment of Hematology/Oncology, Case Western Reserve University, School of Medicine, Cleveland, OH 44106; eUniversity Hospitals Cleveland Medical Center, Cleveland, OH 44106; fDepartment of General Medical Sciences/Oncology, Case Western Reserve University, School of Medicine, Cleveland, OH 44106; and gDepartment of Medicine, Division of Oncology, Stanford University School of Medicine, Stanford, CA 94305 Contributed by George R. Stark, November 10, 2017 (sent for review August 15, 2017; reviewed by Sendurai A. Mani and Ralph R. Weichselbaum) Triple-negative breast cancer (TNBC), the deadliest form of this of a heterogeneous mixture of tumor, immune, endothelial, and disease, lacks a targeted therapy. TNBC tumors that fail to respond stromal cells (7–11). Recent metaanalyses have identified a to chemotherapy are characterized by a repressed IFN/signal trans- number of TNBC subtypes, including two distinguishable by the ducer and activator of transcription (IFN/STAT) gene signature and presence or absence of tumor-infiltrating lymphocytes (TILs) and are often enriched for cancer stem cells (CSCs). We have found that IFN/signal transducer and activator of transcription (IFN/STAT) human mammary epithelial cells that undergo an epithelial-to- signaling (3, 4, 12). Immune-responsive TNBCs are defined by the mesenchymal transition (EMT) following transformation acquire presence of TILs and IFN/STAT signaling, and patients with CSC properties. These mesenchymal/CSCs have a significantly re- immune-responsive tumors have a decreased incidence of re- pressed IFN/STAT gene expression signature and an enhanced ability currence (3, 4, 12). In contrast, TNBCs classified as immune- to migrate and form tumor spheres. Treatment with IFN-beta (IFN-β) repressed lack TILs and evidence of IFN/STAT signaling, are led to a less aggressive epithelial/non–CSC-like state, with repressed more refractory to chemotherapy, and more likely to recur. expression of mesenchymal proteins (VIMENTIN, SLUG), reduced mi- There are three different types of IFNs: Type I (IFNs α and β) gration and tumor sphere formation, and reexpression of CD24 (a Type II (IFN-γ), and Type III (IFN-λ) (13). First identified for their surface marker for non-CSCs), concomitant with an epithelium-like ability to interfere with viral and bacterial replication, the IFNs are MEDICAL SCIENCES morphology. The CSC-like properties were correlated with high lev- also potent immune-modulatory proteins (13, 14). Type I IFNs (α, els of unphosphorylated IFN-stimulated gene factor 3 (U-ISGF3), β) have been most extensively studied in a variety of cancers for which was previously linked to resistance to DNA damage. Inhibiting their antiproliferative and proapoptotic activities, including breast the expression of IRF9 (the DNA-binding component of U-ISGF3) re- cancer (13). Type I IFNs bind to their receptors (IFNAR1/2) duced the migration of mesenchymal/CSCs. Here we report a posi- and activate the receptor-associated kinases JAK1 and TYK2, tive translational role for IFN-β, as gene expression profiling of patient-derived TNBC tumors demonstrates that an IFN-β metagene signature correlates with improved patient survival, an immune re- Significance sponse linked with tumor-infiltrating lymphocytes (TILs), and a re- pressed CSC metagene signature. Taken together, our findings Current cancer therapies fail to repress tumor recurrence and me- indicate that repressed IFN signaling in TNBCs with CSC-like proper- tastasis in triple-negative breast cancer (TNBC) because they fail to ties is due to high levels of U-ISGF3 and that treatment with IFN-β target cells that possess epithelial–mesenchymal (E-M) plasticity reduces CSC properties, suggesting a therapeutic strategy to treat and acquire cancer stem cell (CSC) properties. Identifying and en- drug-resistant, highly aggressive TNBC tumors. gaging signaling pathways that regulate E-M/CSC plasticity within TNBC therefore remains an unmet critical clinical need. Recent ev- triple-negative breast cancer | cancer stem cells | interferon-beta | idence demonstrates that presence of E-M/CSC plasticity in TNBC tumor microenvironment correlates with a repressed interferon/STAT gene signature. Our data demonstrate that exogenous IFN-β targets and represses E-M/ CSC plasticity by reengaging type I IFN signaling in CSC. Our find- riple-negative breast cancer (TNBC), defined by its lack of ings have clinical relevance, as IFN-β signaling correlates with im- estrogen receptor and progesterone receptor expression and T proved patient survival and repressed CSC in TNBC. Thus, our work HER2 amplification, remains the most lethal subtype of breast suggests a therapeutic use for IFN-β in the repression of E-M/CSC– cancer (1–4). Metastasis and tumor recurrence are responsible driven tumor recurrence and metastasis in TNBC. for the majority of deaths in TNBC (1, 5, 6). Highly metastatic TNBC tumors are often composed of cells harboring epithelial– Author contributions: M.R.D., H.C., D.J.J., G.R.S., and M.W.J. designed research; M.R.D. mesenchymal (E-M) plasticity, whereby cancer cells reversibly and D.J.J. performed research; S.V., M.L.T., and J.M.F. contributed prECOG 0105 phase II express epithelial or mesenchymal proteins (7–9). Importantly, clinical trial microarray datasets; M.R.D., H.C., D.J.J., S.V., V.V., G.R.S., and M.W.J. analyzed our laboratory, along with others, has demonstrated that E-M data; V.V. wrote methods describing bioinformatic analyses of prECOG0105 tumor data- plasticity can lead to the emergence of highly migratory, mes- set; and M.R.D., H.C., G.R.S., and M.W.J. wrote the paper. enchymal cancer stem cells (Mes/CSCs) (8–10). In TNBC pa- Reviewers: S.A.M., The University of Texas MD Anderson Cancer Center; and R.R.W., The tients, standard-of-care chemotherapy effectively debulks the University of Chicago. primary tumors by eliminating the more proliferative epithelial The authors declare no conflict of interest. cells, referred to here as epithelial/non-CSCs (Ep/non-CSCs), This open access article is distributed under Creative Commons Attribution-NonCommercial- because they often lack aggressive CSC properties. In contrast, NoDerivatives License 4.0 (CC BY-NC-ND). chemotherapy often fails to target the more slowly growing Mes/ Data deposition: The microarray data reported in this paper have been deposited in the Gene Expression Omnibus (GEO) database, https://www.ncbi.nlm.nih.gov/geo (accession CSCs (10). Identifying the signaling pathways that regulate no. GSE106782). plasticity in TNBC has the potential to provide therapeutic op- 1To whom correspondence may be addressed. Email: [email protected], [email protected], or tions for this difficult disease. [email protected]. Emerging evidence suggests that E-M/CSC plasticity is influ- This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10. enced by the tumor microenvironment (TME). Tumors consist 1073/pnas.1713728114/-/DCSupplemental. www.pnas.org/cgi/doi/10.1073/pnas.1713728114 PNAS Early Edition | 1of6 Downloaded by guest on October 1, 2021 resulting in phosphorylation of cytoplasmic STAT1 and STAT2. Ep MES Ep MES Ep/non-CSC MES/CSC A B C 100% 0.1% Phosphorylated STAT1 and STAT2 bind to IRF9 to form phos- ECADHERIN phorylated IFN-stimulated gene factor 3 (P-ISGF3), the major VIMENTIN B-ACTIN 0% 97% transcription factor complex that drives the expression of hundreds CD24 STAT1 STAT2 IRF9 D E F CD44 of IFN-stimulated genes (ISGs). The , ,and 220 0 200 Ep/non-CSC genesarethemselvestargetsofP-ISGF3, resulting in elevated levels 180 NANOG -0.5 Ep/non-CSC 160 MES/CSC of newly synthesized STAT1, STAT2, and IRF9 proteins, which, -1.0 140 B-ACTIN 120 even without tyrosine phosphorylation, form the related complex, -1.5 100 *** G IRF1 Ep MES -2.0 80 CXCL10 -2.5 MES/CSC 60 unphosphorylated-ISGF3 (U-ISGF3), which can persist for days Log Fraction ISG15 40 IFI44 -3.0 P=8.5e-23 20 following an initial exposure to IFN, resulting in prolonged ex- IFIH1 0 Number Migrated Cells without Tumorspheres 0 10 20 30 40 50 IFIT1 Number Cells Seeded 0 4 8 12162024283236404448 pression of a subset of ISGs. An effective antitumorigenic response IFIT2 Time (hours) IFITM1 to IFN requires the ability to generate a full transcriptional response IFITM2 MX1 HLIJK M following robust P-ISGF3 activation. Unbalanced IFN signaling, IFI16 STAT1 STAT2 IRF9 IRF1 SOCS1 OAS2 IFI27 1.2 1.2 IFI30 1.2 1.0 1.0 1.0 involving a high level of U-ISGF3, engages an IFN-related DNA IFIT3 1.0 1.0 1.0 0.8 0.8 0.8 IRGM 0.8 0.8 0.8 damage resistance gene signature (IRDS) that protects tumor cells PSME1 ** 0.6 0.6 0.6 PHYIN1 0.6 0.6 0.6 *** *** *** STAT1 0.4 0.4 0.4 0.4 0.4 from DNA-damaging chemotherapy and radiation, resulting in STAT2 0.4 *** IRF9 0.2 0.2 0.2 0.2 0.2 0.2 *** therapeutic resistance and poor prognosis in a variety of cancers, IFN Gene Signature Responsive OAS1 0 0 0 0 OAS2 0 0 Ep/non-CSC including TNBC (15, 16). Our laboratory previously demonstrated OAS3 Fold-Change Expression SOCS1 MES/CSC that even a very low level of IFN-β is sufficient to generate U-ISGF3– >2 <2 mediated transcription of genes that correspond to the IRDS (17).
Load more

Recommended publications
  • Activated Peripheral-Blood-Derived Mononuclear Cells
    Transcription factor expression in lipopolysaccharide- activated peripheral-blood-derived mononuclear cells Jared C. Roach*†, Kelly D. Smith*‡, Katie L. Strobe*, Stephanie M. Nissen*, Christian D. Haudenschild§, Daixing Zhou§, Thomas J. Vasicek¶, G. A. Heldʈ, Gustavo A. Stolovitzkyʈ, Leroy E. Hood*†, and Alan Aderem* *Institute for Systems Biology, 1441 North 34th Street, Seattle, WA 98103; ‡Department of Pathology, University of Washington, Seattle, WA 98195; §Illumina, 25861 Industrial Boulevard, Hayward, CA 94545; ¶Medtronic, 710 Medtronic Parkway, Minneapolis, MN 55432; and ʈIBM Computational Biology Center, P.O. Box 218, Yorktown Heights, NY 10598 Contributed by Leroy E. Hood, August 21, 2007 (sent for review January 7, 2007) Transcription factors play a key role in integrating and modulating system. In this model system, we activated peripheral-blood-derived biological information. In this study, we comprehensively measured mononuclear cells, which can be loosely termed ‘‘macrophages,’’ the changing abundances of mRNAs over a time course of activation with lipopolysaccharide (LPS). We focused on the precise mea- of human peripheral-blood-derived mononuclear cells (‘‘macro- surement of mRNA concentrations. There is currently no high- phages’’) with lipopolysaccharide. Global and dynamic analysis of throughput technology that can precisely and sensitively measure all transcription factors in response to a physiological stimulus has yet to mRNAs in a system, although such technologies are likely to be be achieved in a human system, and our efforts significantly available in the near future. To demonstrate the potential utility of advanced this goal. We used multiple global high-throughput tech- such technologies, and to motivate their development and encour- nologies for measuring mRNA levels, including massively parallel age their use, we produced data from a combination of two distinct signature sequencing and GeneChip microarrays.
    [Show full text]
  • A Molecular Switch from STAT2-IRF9 to ISGF3 Underlies Interferon-Induced Gene Transcription
    ARTICLE https://doi.org/10.1038/s41467-019-10970-y OPEN A molecular switch from STAT2-IRF9 to ISGF3 underlies interferon-induced gene transcription Ekaterini Platanitis 1, Duygu Demiroz1,5, Anja Schneller1,5, Katrin Fischer1, Christophe Capelle1, Markus Hartl 1, Thomas Gossenreiter 1, Mathias Müller2, Maria Novatchkova3,4 & Thomas Decker 1 Cells maintain the balance between homeostasis and inflammation by adapting and inte- grating the activity of intracellular signaling cascades, including the JAK-STAT pathway. Our 1234567890():,; understanding of how a tailored switch from homeostasis to a strong receptor-dependent response is coordinated remains limited. Here, we use an integrated transcriptomic and proteomic approach to analyze transcription-factor binding, gene expression and in vivo proximity-dependent labelling of proteins in living cells under homeostatic and interferon (IFN)-induced conditions. We show that interferons (IFN) switch murine macrophages from resting-state to induced gene expression by alternating subunits of transcription factor ISGF3. Whereas preformed STAT2-IRF9 complexes control basal expression of IFN-induced genes (ISG), both type I IFN and IFN-γ cause promoter binding of a complete ISGF3 complex containing STAT1, STAT2 and IRF9. In contrast to the dogmatic view of ISGF3 formation in the cytoplasm, our results suggest a model wherein the assembly of the ISGF3 complex occurs on DNA. 1 Max Perutz Labs (MPL), University of Vienna, Vienna 1030, Austria. 2 Institute of Animal Breeding and Genetics, University of Veterinary Medicine Vienna, Vienna 1210, Austria. 3 Institute of Molecular Biotechnology of the Austrian Academy of Sciences (IMBA), Vienna 1030, Austria. 4 Research Institute of Molecular Pathology (IMP), Vienna Biocenter (VBC), Vienna 1030, Austria.
    [Show full text]
  • Review Article the Role of Interferon Regulatory Factor-1 (IRF1) in Overcoming Antiestrogen Resistance in the Treatment of Breast Cancer
    SAGE-Hindawi Access to Research International Journal of Breast Cancer Volume 2011, Article ID 912102, 9 pages doi:10.4061/2011/912102 Review Article The Role of Interferon Regulatory Factor-1 (IRF1) in Overcoming Antiestrogen Resistance in the Treatment of Breast Cancer J.L.Schwartz,A.N.Shajahan,andR.Clarke Georgetown University Medical Center, W401 Research Building, 3970 Reservoir Road, NW, Washington, DC 20057, USA Correspondence should be addressed to R. Clarke, [email protected] Received 18 February 2011; Revised 29 April 2011; Accepted 9 May 2011 Academic Editor: Chengfeng Yang Copyright © 2011 J. L. Schwartz et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Resistance to endocrine therapy is common among breast cancer patients with estrogen receptor alpha-positive (ER+) tumors and limits the success of this therapeutic strategy. While the mechanisms that regulate endocrine responsiveness and cell fate are not fully understood, interferon regulatory factor-1 (IRF1) is strongly implicated as a key regulatory node in the underlying signaling network. IRF1 is a tumor suppressor that mediates cell fate by facilitating apoptosis and can do so with or without functional p53. Expression of IRF1 is downregulated in endocrine-resistant breast cancer cells, protecting these cells from IRF1- induced inhibition of proliferation and/or induction of cell death. Nonetheless, when IRF1 expression is induced following IFNγ treatment, antiestrogen sensitivity is restored by a process that includes the inhibition of prosurvival BCL2 family members and caspase activation.
    [Show full text]
  • To Study Mutant P53 Gain of Function, Various Tumor-Derived P53 Mutants
    Differential effects of mutant TAp63γ on transactivation of p53 and/or p63 responsive genes and their effects on global gene expression. A thesis submitted in partial fulfillment of the requirements for the degree of Master of Science By Shama K Khokhar M.Sc., Bilaspur University, 2004 B.Sc., Bhopal University, 2002 2007 1 COPYRIGHT SHAMA K KHOKHAR 2007 2 WRIGHT STATE UNIVERSITY SCHOOL OF GRADUATE STUDIES Date of Defense: 12-03-07 I HEREBY RECOMMEND THAT THE THESIS PREPARED UNDER MY SUPERVISION BY SHAMA KHAN KHOKHAR ENTITLED Differential effects of mutant TAp63γ on transactivation of p53 and/or p63 responsive genes and their effects on global gene expression BE ACCEPTED IN PARTIAL FULFILLMENT OF THE REQUIREMENTS FOR THE DEGREE OF Master of Science Madhavi P. Kadakia, Ph.D. Thesis Director Daniel Organisciak , Ph.D. Department Chair Committee on Final Examination Madhavi P. Kadakia, Ph.D. Steven J. Berberich, Ph.D. Michael Leffak, Ph.D. Joseph F. Thomas, Jr., Ph.D. Dean, School of Graduate Studies 3 Abstract Khokhar, Shama K. M.S., Department of Biochemistry and Molecular Biology, Wright State University, 2007 Differential effect of TAp63γ mutants on transactivation of p53 and/or p63 responsive genes and their effects on global gene expression. p63, a member of the p53 gene family, known to play a role in development, has more recently also been implicated in cancer progression. Mice lacking p63 exhibit severe developmental defects such as limb truncations, abnormal skin, and absence of hair follicles, teeth, and mammary glands. Germline missense mutations of p63 have been shown to be responsible for several human developmental syndromes including SHFM, EEC and ADULT syndromes and are associated with anomalies in the development of organs of epithelial origin.
    [Show full text]
  • The Proapoptotic Gene Interferon Regulatory Factor-1 Mediates the Antiproliferative Outcome of Paired Box 2 Gene and Tamoxifen
    Oncogene (2020) 39:6300–6312 https://doi.org/10.1038/s41388-020-01435-4 ARTICLE The proapoptotic gene interferon regulatory factor-1 mediates the antiproliferative outcome of paired box 2 gene and tamoxifen 1 1 1 2 3 3 Shixiong Wang ● Venkata S. Somisetty ● Baoyan Bai ● Igor Chernukhin ● Henri Niskanen ● Minna U. Kaikkonen ● 4,5 2 6,7 Meritxell Bellet ● Jason S. Carroll ● Antoni Hurtado Received: 13 November 2019 / Revised: 5 August 2020 / Accepted: 17 August 2020 / Published online: 25 August 2020 © The Author(s) 2020. This article is published with open access Abstract Tamoxifen is the most prescribed selective estrogen receptor (ER) modulator in patients with ER-positive breast cancers. Tamoxifen requires the transcription factor paired box 2 protein (PAX2) to repress the transcription of ERBB2/HER2. Now, we identified that PAX2 inhibits cell growth of ER+/HER2− tumor cells in a dose-dependent manner. Moreover, we have identified that cell growth inhibition can be achieved by expressing moderate levels of PAX2 in combination with tamoxifen treatment. Global run-on sequencing of cells overexpressing PAX2, when coupled with PAX2 ChIP-seq, identified common targets regulated by both PAX2 and tamoxifen. The data revealed that PAX2 can inhibit estrogen-induced gene transcription 1234567890();,: 1234567890();,: and this effect is enhanced by tamoxifen, suggesting that they converge on repression of the same targets. Moreover, PAX2 and tamoxifen have an additive effect and both induce coding genes and enhancer RNAs (eRNAs). PAX2–tamoxifen upregulated genes are also enriched with PAX2 eRNAs. The enrichment of eRNAs is associated with the highest expression of genes that positivity regulate apoptotic processes.
    [Show full text]
  • HHS Public Access Author Manuscript
    HHS Public Access Author manuscript Author Manuscript Author ManuscriptGenes Dis Author Manuscript. Author manuscript; Author Manuscript available in PMC 2015 March 24. Published in final edited form as: Genes Dis. 2015 March ; 2(1): 46–56. doi:10.1016/j.gendis.2014.10.003. The roles of interferon-inducible p200 family members IFI16 and p204 in innate immune responses, cell differentiation and proliferation Hua Zhaoa,b, Elena Gonzalezgugela, Lei Chengb, Brendon Richbourgha, Lin Nieb,*, and Chuanju Liua,c aDepartment of Orthopaedic Surgery, New York University School of Medicine, New York, NY 10003, United States bDepartment of Spine Surgery, Qilu Hospital of Shandong University, Jinan, 250014, China cDepartment of Cell Biology, New York University School of Medicine, New York, NY 10016, United States Abstract p204 is a member of the interferon-inducible p200 family proteins in mice. The p200 family has been reported to be multifunctional regulators of cell proliferation, differentiation, apoptosis and senescence. Interferon-inducible protein 16 (IFI16) is regarded as the human ortholog of p204 in several studies. This is possibly due to the similarity of their structures. However the consistency of their functions is still elusive. Currently, an emerging focus has been placed upon the role of the p200 proteins as sensors for microbial DNA in innate immune responses and provides new insights into infections as well as autoimmune diseases. This review specially focuses on IFI16 and p204, the member of p200 family in human and murine respectively, and their pathophysiological roles in innate immune responses, cell differentiation and proliferation. Keywords DNA sensor; IFI16; Innate immune; response; Multifunctional; regulator; p204 Introduction p204 is a multifunctional interferon-inducible murine protein in the p200 family (also known as PYHIN or HIN-200 proteins).
    [Show full text]
  • Ten Commandments for a Good Scientist
    Unravelling the mechanism of differential biological responses induced by food-borne xeno- and phyto-estrogenic compounds Ana María Sotoca Covaleda Wageningen 2010 Thesis committee Thesis supervisors Prof. dr. ir. Ivonne M.C.M. Rietjens Professor of Toxicology Wageningen University Prof. dr. Albertinka J. Murk Personal chair at the sub-department of Toxicology Wageningen University Thesis co-supervisor Dr. ir. Jacques J.M. Vervoort Associate professor at the Laboratory of Biochemistry Wageningen University Other members Prof. dr. Michael R. Muller, Wageningen University Prof. dr. ir. Huub F.J. Savelkoul, Wageningen University Prof. dr. Everardus J. van Zoelen, Radboud University Nijmegen Dr. ir. Toine F.H. Bovee, RIKILT, Wageningen This research was conducted under the auspices of the Graduate School VLAG Unravelling the mechanism of differential biological responses induced by food-borne xeno- and phyto-estrogenic compounds Ana María Sotoca Covaleda Thesis submitted in fulfillment of the requirements for the degree of doctor at Wageningen University by the authority of the Rector Magnificus Prof. dr. M.J. Kropff, in the presence of the Thesis Committee appointed by the Academic Board to be defended in public on Tuesday 14 September 2010 at 4 p.m. in the Aula Unravelling the mechanism of differential biological responses induced by food-borne xeno- and phyto-estrogenic compounds. Ana María Sotoca Covaleda Thesis Wageningen University, Wageningen, The Netherlands, 2010, With references, and with summary in Dutch. ISBN: 978-90-8585-707-5 “Caminante no hay camino, se hace camino al andar. Al andar se hace camino, y al volver la vista atrás se ve la senda que nunca se ha de volver a pisar” - Antonio Machado – A mi madre.
    [Show full text]
  • Genome-Scale Identification of Transcription Factors That Mediate An
    ARTICLE DOI: 10.1038/s41467-018-04406-2 OPEN Genome-scale identification of transcription factors that mediate an inflammatory network during breast cellular transformation Zhe Ji 1,2,4, Lizhi He1, Asaf Rotem1,2,5, Andreas Janzer1,6, Christine S. Cheng2,7, Aviv Regev2,3 & Kevin Struhl 1 Transient activation of Src oncoprotein in non-transformed, breast epithelial cells can initiate an epigenetic switch to the stably transformed state via a positive feedback loop that involves 1234567890():,; the inflammatory transcription factors STAT3 and NF-κB. Here, we develop an experimental and computational pipeline that includes 1) a Bayesian network model (AccessTF) that accurately predicts protein-bound DNA sequence motifs based on chromatin accessibility, and 2) a scoring system (TFScore) that rank-orders transcription factors as candidates for being important for a biological process. Genetic experiments validate TFScore and suggest that more than 40 transcription factors contribute to the oncogenic state in this model. Interestingly, individual depletion of several of these factors results in similar transcriptional profiles, indicating that a complex and interconnected transcriptional network promotes a stable oncogenic state. The combined experimental and computational pipeline represents a general approach to comprehensively identify transcriptional regulators important for a biological process. 1 Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA. 2 Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA. 3 Department of Biology, Howard Hughes Medical Institute and David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 20140, USA. 4Present address: Department of Pharmacology and Biomedical Engineering, Northwestern University, Evanston 60611 IL, USA.
    [Show full text]
  • A Dual Cis-Regulatory Code Links IRF8 to Constitutive and Inducible Gene Expression in Macrophages
    Downloaded from genesdev.cshlp.org on October 1, 2021 - Published by Cold Spring Harbor Laboratory Press A dual cis-regulatory code links IRF8 to constitutive and inducible gene expression in macrophages Alessandra Mancino,1,3 Alberto Termanini,1,3 Iros Barozzi,1 Serena Ghisletti,1 Renato Ostuni,1 Elena Prosperini,1 Keiko Ozato,2 and Gioacchino Natoli1 1Department of Experimental Oncology, European Institute of Oncology (IEO), 20139 Milan, Italy; 2Laboratory of Molecular Growth Regulation, Genomics of Differentiation Program, National Institute of Child Health and Human Development (NICHD), National Institutes of Health, Bethesda, Maryland 20892, USA The transcription factor (TF) interferon regulatory factor 8 (IRF8) controls both developmental and inflammatory stimulus-inducible genes in macrophages, but the mechanisms underlying these two different functions are largely unknown. One possibility is that these different roles are linked to the ability of IRF8 to bind alternative DNA sequences. We found that IRF8 is recruited to distinct sets of DNA consensus sequences before and after lipopolysaccharide (LPS) stimulation. In resting cells, IRF8 was mainly bound to composite sites together with the master regulator of myeloid development PU.1. Basal IRF8–PU.1 binding maintained the expression of a broad panel of genes essential for macrophage functions (such as microbial recognition and response to purines) and contributed to basal expression of many LPS-inducible genes. After LPS stimulation, increased expression of IRF8, other IRFs, and AP-1 family TFs enabled IRF8 binding to thousands of additional regions containing low-affinity multimerized IRF sites and composite IRF–AP-1 sites, which were not premarked by PU.1 and did not contribute to the basal IRF8 cistrome.
    [Show full text]
  • Induced IFN Regulatory Factor 1 Transcription Factor by Myd88 in Toll-Like Receptor-Dependent Gene Induction Program
    Evidence for licensing of IFN-␥-induced IFN regulatory factor 1 transcription factor by MyD88 in Toll-like receptor-dependent gene induction program Hideo Negishi*, Yasuyuki Fujita*, Hideyuki Yanai*, Shinya Sakaguchi*, Xinshou Ouyang*, Masahiro Shinohara†, Hiroshi Takayanagi†, Yusuke Ohba*, Tadatsugu Taniguchi*‡, and Kenya Honda* *Department of Immunology, Graduate School of Medicine and Faculty of Medicine, University of Tokyo, Hongo 7-3-1, Bunkyo-ku, Tokyo 113-0033, Japan; and †Department of Cell Signaling, Graduate School, Tokyo Medical and Dental University, Yushima 1-5-45, Bunkyo-ku, Tokyo 113-8549, Japan Contributed by Tadatsugu Taniguchi, August 18, 2006 The recognition of microbial components by Toll-like receptors (TLRs) In the present study we investigated how IFN-␥-induced IRF1 initiates signal transduction pathways, which trigger the expression contributes to TLR-mediated signaling. We demonstrate that of a series of target genes. It has been reported that TLR signaling is IRF1 forms a complex with MyD88, similar to the case of IRF4, enhanced by cytokines such as IFN-␥, but the mechanisms underlying IRF5, and IRF7. We also provide evidence that IRF1 induced this enhancement remain unclear. The MyD88 adaptor, which is by IFN-␥ is activated by MyD88, which we refer to as ‘‘licensing,’’ essential for signaling by many TLRs, recruits members of the IFN and migrates rapidly into the nucleus to mediate an efficient regulatory factor (IRF) family of transcription factors, such as IRF5 and induction of IFN-␤, iNOS, and IL-12p35. Our study therefore IRF7, to evoke the activation of TLR target genes. In this study we revealed that IRF1 is a previously unidentified member of the demonstrate that IRF1, which is induced by IFN-␥, also interacts with multimolecular complex organized via MyD88 and that the IRF1 and is activated by MyD88 upon TLR activation.
    [Show full text]
  • Irf1) Signaling Regulates Apoptosis and Autophagy to Determine Endocrine Responsiveness and Cell Fate in Human Breast Cancer
    INTERFERON REGULATORY FACTOR-1 (IRF1) SIGNALING REGULATES APOPTOSIS AND AUTOPHAGY TO DETERMINE ENDOCRINE RESPONSIVENESS AND CELL FATE IN HUMAN BREAST CANCER A Dissertation Submitted to the Faculty of the Graduate School of Arts and Sciences of Georgetown University in partial fulfillment of the requirements for the degree of Doctor of Philosophy in Physiology & Biophysics By Jessica L. Roberts, B.S. Washington, DC September 27, 2013 Copyright 2013 by Jessica L. Roberts All Rights Reserved ii INTERFERON REGULATORY FACTOR-1 (IRF1) SIGNALING REGULATES APOPTOSIS AND AUTOPHAGY TO DETERMINE ENDOCRINE RESPONSIVENESS AND CELL FATE IN HUMAN BREAST CANCER Jessica L. Roberts, B.S. Thesis Advisor: Robert Clarke, Ph.D. ABSTRACT Interferon regulatory factor-1 (IRF1) is a nuclear transcription factor and pivotal regulator of cell fate in cancer cells. While IRF1 is known to possess tumor suppressive activities, the role of IRF1 in mediating apoptosis and autophagy in breast cancer is largely unknown. Here, we show that IRF1 inhibits antiapoptotic B-cell lymphoma 2 (BCL2) protein expression, whose overexpression often contributes to antiestrogen resistance. We proposed that directly targeting the antiapoptotic BCL2 members with GX15-070 (GX; obatoclax), a BH3-mimetic currently in clinical development, would be an attractive strategy to overcome antiestrogen resistance in some breast cancers. Inhibition of BCL2 activity, through treatment with GX, was more effective in reducing the cell density of antiestrogen resistant breast cancer cells versus sensitive cells, and this increased sensitivity correlated with an accumulation of autophagic vacuoles. While GX treatment promoted autophagic vacuole and autolysosome formation, p62/SQSTM1, a marker for autophagic degradation, levels accumulated.
    [Show full text]
  • IFI16 and Cgas Cooperate in the Activation of STING During DNA Sensing in Human Keratinocytes
    ARTICLE Received 15 Dec 2015 | Accepted 22 Dec 2016 | Published 13 Feb 2017 DOI: 10.1038/ncomms14392 OPEN IFI16 and cGAS cooperate in the activation of STING during DNA sensing in human keratinocytes Jessica F. Almine1,2,*, Craig A.J. O’Hare1,2,*, Gillian Dunphy1,2, Ismar R. Haga3, Rangeetha J. Naik1, Abdelmadjid Atrih4, Dympna J. Connolly5, Jordan Taylor1, Ian R. Kelsall1, Andrew G. Bowie5, Philippa M. Beard3,6 & Leonie Unterholzner1,2 Many human cells can sense the presence of exogenous DNA during infection though the cytosolic DNA receptor cyclic GMP-AMP synthase (cGAS), which produces the second messenger cyclic GMP-AMP (cGAMP). Other putative DNA receptors have been described, but whether their functions are redundant, tissue-specific or integrated in the cGAS-cGAMP pathway is unclear. Here we show that interferon-g inducible protein 16 (IFI16) cooperates with cGAS during DNA sensing in human keratinocytes, as both cGAS and IFI16 are required for the full activation of an innate immune response to exogenous DNA and DNA viruses. IFI16 is also required for the cGAMP-induced activation of STING, and interacts with STING to promote STING phosphorylation and translocation. We propose that the two DNA sensors IFI16 and cGAS cooperate to prevent the spurious activation of the type I interferon response. 1 Division of Cell Signalling and Immunology, School of Life Sciences, University of Dundee, Dundee DD1 5EH, UK. 2 Division of Biomedical and Life Sciences, Faculty of Health and Medicine, Lancaster University, Lancaster LA1 4YQ, UK. 3 The Pirbright Institute, Pirbright, Surrey GU24 0NF, UK. 4 Fingerprints Proteomics Facility, School of Life Sciences, University of Dundee, Dundee DD1 5EH, UK.
    [Show full text]